52 related articles for article (PubMed ID: 1559663)
1. [A study of the absorption of NPH insulin administered into subcutaneous tissue: in vitro study of the mechanism of insulin release from NPH insulin crystal].
Yanagisawa K
Hokkaido Igaku Zasshi; 1992 Jan; 67(1):81-8. PubMed ID: 1559663
[TBL] [Abstract][Full Text] [Related]
2. Structural characterization of insulin NPH formulations.
Norrman M; Hubálek F; Schluckebier G
Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105
[TBL] [Abstract][Full Text] [Related]
3. ["In vitro" protaminase activity of human plasma and serum and the human carboxypeptidase N (author's transl)].
Blass J; Verriest C; Vicaigne MB; Weiss M
Pathol Biol (Paris); 1980 Oct; 28(8):527-34. PubMed ID: 6448971
[TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin.
Blanco C; Castillo R; Quiralte J; Delgado J; García I; de Pablos P; Carrillo T
Allergy; 1996 Jun; 51(6):421-4. PubMed ID: 8837667
[TBL] [Abstract][Full Text] [Related]
5. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro.
Duchateau J; Schreyen H; Dorchy H
Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.
Levy JH; Zaidan JR; Faraj B
Anesth Analg; 1986 Jul; 65(7):739-42. PubMed ID: 2424341
[TBL] [Abstract][Full Text] [Related]
7. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus.
Nicolau GY; Haus E; Lakatua DJ; Bogdan C; Petrescu E; Sackett-Lundeen L; Stelea S; Stelea P
Endocrinologie; 1984; 22(1):3-16. PubMed ID: 6369501
[TBL] [Abstract][Full Text] [Related]
8. Hybrid insulin cocrystals for controlled release delivery.
Brader ML; Sukumar M; Pekar AH; McClellan DS; Chance RE; Flora DB; Cox AL; Irwin L; Myers SR
Nat Biotechnol; 2002 Aug; 20(8):800-4. PubMed ID: 12134168
[TBL] [Abstract][Full Text] [Related]
9. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
Luzio SD; Beck P; Owens DR
Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
[TBL] [Abstract][Full Text] [Related]
11. NPH human insulin: does it work in a once-a-day regimen?
Gadia M; Sosenko JM; Salzman R; Lauritano AA; Haycock P
Clin Ther; 1989; 11(1):120-8. PubMed ID: 2720723
[TBL] [Abstract][Full Text] [Related]
12. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects.
Burke B; Andrews WJ; Hadden DR
Diabetes Res; 1987 Apr; 4(4):163-7. PubMed ID: 3304782
[TBL] [Abstract][Full Text] [Related]
14. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
15. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
16. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
17. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue.
DeFelippis MR; Bakaysa DL; Bell MA; Heady MA; Li S; Pye S; Youngman KM; Radziuk J; Frank BH
J Pharm Sci; 1998 Feb; 87(2):170-6. PubMed ID: 9519149
[TBL] [Abstract][Full Text] [Related]
20. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
